CEO Tim Van Hauwermeiren emphasized 2024 as a "phenomenal year," highlighted by expanding the reach of VYVGART to over 10,000 patients globally across three approved indications. He noted the ...

The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.A recent comprehensive analysis of the Chronic ...

HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing ...

Roughly 85% of those CIDP patients have switched over to Vyvgart from intravenous immunoglobulin treatment, in line with argenx’s expectations prior to the launch, Massey pointed out.

Etanercept, a fusion protein that binds primarily to soluble TNF, has been investigated in 10 patients with treatment-resistant CIDP, 3 of whom showed definite clinical improvement and another 3 ...

Argenx’s ad focuses on two people with CIDP, played by actors but inspired by the patient community. The ad opens with a woman heading toward a car with the support of a walking stick.

Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profileof VYVGART and VYVGART HytrulogMG patients on VYVGART ...

We expanded our reach to over 10,000 patients globally across 3 approved indications and delivered significant impacts to the CIDP community early into launch. We also achieved several key ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported ...